NovAliX
Integrated drug discovery services for pharmaceutical and biotech companies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
* | N/A | Late VC | |
| Total Funding | 000k | ||
Related Content
NovAliX is a contract research organization (CRO) that provides integrated services to support the drug discovery programs of pharmaceutical and biotechnology companies. The company specializes in the preclinical stages of drug development, offering expertise in chemistry and biophysics. Its services aim to advance therapeutic projects from hit identification to the selection of preclinical candidates.
The company was founded in 2002 by Denis Zeyer, Luc Van Hijfte, and Stephan Jenn, originating as a spin-off from the Institute of Science and Supramolecular Engineering (ISIS) at the University of Strasbourg, France. The founders combined their expertise in chemistry and biophysics to establish a research-focused organization. In 2015, NovAliX expanded its capabilities by acquiring Graffinity, a German company specializing in small molecule screening.
NovAliX operates on a fee-for-service business model, providing its clients with access to its scientific teams and technological platforms. These platforms include capabilities in cryo-electron microscopy (cryo-EM), X-ray crystallography, and various chemistry services like synthesis and medicinal chemistry. The company serves a global client base, ranging from small biotech startups to large pharmaceutical corporations, helping them to de-risk and accelerate their research and development pipelines.
Keywords: drug discovery, contract research organization, biophysics, medicinal chemistry, cryo-EM, X-ray crystallography, preclinical research, biotechnology, pharmaceutical services, hit-to-lead